Obio Technology (Shanghai)
Latest round
- Series C
Last raised
- Dec 2020
Total raised
- $77M
Investors
- 11
About Obio Technology (Shanghai)
,Ltd. operates as a biopharmaceutical company that focuses on gene therapy field., Ltd. The company established gene therapy manufacturing platform (GMP) in 2016. QuaCell Biotechnology has become the strategic partner of the company in March 2021. The company passed ISO9001:2015 quality management system certification. The company provides contract research organization (CRO) service, such as gene therapy vector development, gene function research, drug target and efficacy research. The company also provides contract development and manufacturing organization (CDMO) service, such as process development and testing, IND-CMC pharmaceutical research, clinical samples GMP production. The company's platform provides holistic CDMO services for scientists, research facilities and medical institutions. The company's products include plasmid, adeno-associated virus, lentivirus and cell therapy products.
Who invested in Obio Technology (Shanghai)
11 investors across 4 rounds
See all investors in Obio Technology (Shanghai)
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Obio Technology (Shanghai)
Who invested in Obio Technology (Shanghai)?
Obio Technology (Shanghai) has 11 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Obio Technology (Shanghai) raised?
Obio Technology (Shanghai) has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Obio Technology (Shanghai) last raise money?
Obio Technology (Shanghai)'s most recent round on record is a Series C, in Dec 2020.
What does Obio Technology (Shanghai) do?
Obio Technology (Shanghai) is a biotechnology company.
Where is Obio Technology (Shanghai) headquartered?
Obio Technology (Shanghai) is headquartered in Shanghai, China.
Which VCs invest in companies like Obio Technology (Shanghai)?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Obio Technology (Shanghai)'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Obio Technology (Shanghai)? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.